+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neutropenia Biologic Drug Treatment Global Market Report 2020-30: COVID-19 Growth and Change

  • ID: 5214721
  • Report
  • December 2020
  • Region: Global
  • 200 pages
  • The Business Research Company
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Amgen
  • Cellerant Therapeutics
  • Dong-A ST Co.
  • Myelo Therapeutics
  • Novartis
  • Pfizer
  • MORE
Neutropenia Biologic Drug Treatment Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global neutropenia biologic drug treatment market.

This report focuses on neutropenia biologic drug treatment market which is experiencing strong growth. The report gives a guide to the neutropenia biologic drug treatment market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the neutropenia biologic drug treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Neutropenia Biologic Drug Treatment market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider neutropenia biologic drug treatment market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The neutropenia biologic drug treatment market section of the report gives context. It compares the neutropenia biologic drug treatment market with other segments of the neutropenia biologic drug treatment market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, neutropenia biologic drug treatment indicators comparison.
Scope

Markets Covered:
1) By Drug Type: Filgrastim; Pegfilgrastim; Lenograstim; Lipegfilgrastim; Sargramostim
2) By Treatment Type: Antibiotic Drugs; Granulocyte-Colony-Stimulating Factor (G-CSF); Antifungal Drugs; Others
3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Pharmacies

Companies Mentioned: Teva Pharmaceutical; Amgen; Sanofi; Mylan; Kyowa Kirin

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen
  • Cellerant Therapeutics
  • Dong-A ST Co.
  • Myelo Therapeutics
  • Novartis
  • Pfizer
  • MORE
1. Executive Summary

2. Neutropenia Biologic Drug Treatment Market Characteristics

3. Neutropenia Biologic Drug Treatment Market Size and Growth
3.1. Global Neutropenia Biologic Drug Treatment Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Neutropenia Biologic Drug Treatment Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Neutropenia Biologic Drug Treatment Market Segmentation
4.1. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Filgrastim
  • Pegfilgrastim
  • Lenograstim
  • Lipegfilgrastim
  • Sargramostim
4.2. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Antibiotic Drugs
  • Granulocyte-Colony-Stimulating Factor (G-CSF)
  • Antifungal Drugs
  • Others
4.3. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
5. Neutropenia Biologic Drug Treatment Market Regional and Country Analysis
5.1. Global Neutropenia Biologic Drug Treatment Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Neutropenia Biologic Drug Treatment Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

6. Asia-Pacific Neutropenia Biologic Drug Treatment Market
6.1. Asia-Pacific Neutropenia Biologic Drug Treatment Market Overview
6.2. Asia-Pacific Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

7. China Neutropenia Biologic Drug Treatment Market
7.1. China Neutropenia Biologic Drug Treatment Market Overview
7.2. China Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion
7.3. China Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

8. India Neutropenia Biologic Drug Treatment Market
8.1. India Neutropenia Biologic Drug Treatment Market Overview
8.2. India Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
8.3. India Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

9. Japan Neutropenia Biologic Drug Treatment Market
9.1. Japan Neutropenia Biologic Drug Treatment Market Overview
9.2. Japan Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
9.3. Japan Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

10. Australia Neutropenia Biologic Drug Treatment Market
10.1. Australia Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
10.2. Australia Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

11. Indonesia Neutropenia Biologic Drug Treatment Market
11.1. Indonesia Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
11.2. Indonesia Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

12. South Korea Neutropenia Biologic Drug Treatment Market
12.1. South Korea Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
12.2. South Korea Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

13. Western Europe Neutropenia Biologic Drug Treatment Market
13.1. Western Europe Neutropenia Biologic Drug Treatment Market Overview
13.2. Western Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
13.3. Western Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

14. UK Neutropenia Biologic Drug Treatment Market
14.1. UK Neutropenia Biologic Drug Treatment Market Overview
14.2. UK Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
14.3. UK Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

15. Germany Neutropenia Biologic Drug Treatment Market
15.1. Germany Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
15.2. Germany Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

16. France Neutropenia Biologic Drug Treatment Market
16.4. France Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
16.5. France Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

17. Eastern Europe Neutropenia Biologic Drug Treatment Market
17.1. Eastern Europe Neutropenia Biologic Drug Treatment Market Overview
17.2. Eastern Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

18. Russia Neutropenia Biologic Drug Treatment Market
18.1. Russia Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
18.2. Russia Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

19. North America Neutropenia Biologic Drug Treatment Market
19.1. North America Neutropenia Biologic Drug Treatment Market Overview
19.2. North America Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
19.3. North America Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

20. USA Neutropenia Biologic Drug Treatment Market
20.1. USA Neutropenia Biologic Drug Treatment Market Overview
20.2. USA Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
20.3. USA Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

21. South America Neutropenia Biologic Drug Treatment Market
21.1. South America Neutropenia Biologic Drug Treatment Market Overview
21.2. South America Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
21.3. South America Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

22. Brazil Neutropenia Biologic Drug Treatment Market
22.1. Brazil Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
22.2. Brazil Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

23. Middle East Neutropenia Biologic Drug Treatment Market
23.1. Middle East Neutropenia Biologic Drug Treatment Market Overview
23.2. Middle East Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
23.3. Middle East Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

24. Africa Neutropenia Biologic Drug Treatment Market
24.1. Africa Neutropenia Biologic Drug Treatment Market Overview
24.2. Africa Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
24.3. Africa Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

25. Neutropenia Biologic Drug Treatment Market Competitive Landscape and Company Profiles
25.1. Neutropenia Biologic Drug Treatment Market Competitive Landscape
25.2. Neutropenia Biologic Drug Treatment Market Company Profiles
25.2.1. Teva Pharmaceutical
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Amgen
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Sanofi
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Mylan
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Kyowa Kirin
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers and Acquisitions In The Neutropenia Biologic Drug Treatment Market

27. Neutropenia Biologic Drug Treatment Market Trends and Strategies

28. Neutropenia Biologic Drug Treatment Market Future Outlook and Potential Analysis

29. Appendix
29.1. Abbreviations
29.2. Currencies
29.3. Research Inquiries
29.4. About the Publisher
29.5. Copyright and Disclaimer
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Amgen
  • Cellerant Therapeutics
  • Dong-A ST Co.
  • Myelo Therapeutics
  • Novartis
  • Pfizer
  • MORE
Major players in the neutropenia biologic drug treatment market are Teva Pharmaceutical, Amgen, Sanofi, Mylan, Kyowa Kirin, Baxter International, CVS Health Corp, Novartis, Spectrum Pharmaceuticals, and Partner Therapeutics.

The global neutropenia biologic drug treatment market is expected to decline from $12.22 billion in 2019 to $11.54 billion in 2020 at a compound annual growth rate (CAGR) of -5.54%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $13.34 billion in 2023 at a CAGR of 4.95%.

The neutropenia biologic drug treatment market consists of sales of biologics used for the treatment of neutropenia and related services by entities (organizations, sole traders and partnerships) that produce biologics for neutropenia treatment. Neutropenia is a clinical condition characterized by a decrease in neutrophil count in the blood, resulting in a higher risk of developing serious infections. A neutrophil is a type of white blood cell, which helps in fighting infections. The major causes of neutropenia include cancer chemotherapy, infections, bone marrow disorders, autoimmune disorders, and the use of specific drugs. The market consists of revenue generated by the companies manufacturing the neutropenia biologic drugs by the sales of these products.

North America was the largest region in the neutropenia biologic drug treatment market in 2019. Asia-Pacific is expected to be the fastest-growing region in the forecast period.

In February 2018, Partner Therapeutics, a Boston-based cancer company, acquired Leukine (Sargramostim) from Sanofi for $60 million. Leukine is the only FDA-approved recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and it is indicated for the treatment of acute myelogenous leukemia (AML) in older adults both in allogeneic and autologous bone marrow transplantation. This acquisition provides a commercial business to Partner Therapeutics and also to make it a core component of the immune-oncology segment. Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris.

The neutropenia biologic drug treatment market covered in this report is segmented by drug type into filgrastim; pegfilgrastim; lenograstim; lipegfilgrastim; sargramostim. It is also segmented by treatment type into antibiotic drugs; granulocyte-colony-stimulating factor (G-CSF); antifungal drugs; others and by distribution channel into retail pharmacies; hospital pharmacies; online pharmacies.

The introduction of biosimilars as a result of patent expiry is expected to hamper the growth of the neutropenia biologic drug treatment market. Biosimilar is a therapeutic agent, which has high similarity with the original biological product in action but is available at a lower cost than the cost of the original product. Biosimilars are mostly priced at 70% of the branded drug price and are likely to replace expensive branded drugs. For instance, Novartis AG launched a biosimilar drug, Zarxio, which has substituted Amgen’s branded biologic drug, Neupogen. These less expensive alternatives increase competition in the biologics market putting downward pressure on pricing and market value growth.

Companies in the neutropenia biologic drug treatment market are increasingly investing in developing novel drug delivery systems to improve the therapeutic response of the drug and increase its efficacy. Novel drug delivery systems allow the delivery of a very high dose of drugs directly into the neutrophils, while the systemic dose remains low, thus disallowing side-effects. For instance, in August 2020, Asalyxa Bio announced its formation and seed funding to accelerate ASX-100 into first-in-human trials in 2021. ASX-100 is a novel spherical particle that releases a safe and effective anti-inflammatory agent, salicylic acid, directly to over-reactive immune cells, and is used for treating severe neutrophil-mediated disease.

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the neutropenia biologic drugs market. Due to a growing cancer incidence and an increase in the number of people opting for chemotherapy, there has been an increasing incidence in the number of people suffering from neutropenia. According to a 2019 study by Cancer.net, around 50% of the people with cancer who are undergoing chemotherapy have some level of neutropenia. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the neutropenia biologic drug treatment market over the forthcoming years.
Note: Product cover images may vary from those shown
4 of 5
  • Teva Pharmaceutical
  • Amgen
  • Sanofi
  • Mylan
  • Kyowa Kirin
  • Baxter International
  • CVS Health Corp
  • Novartis
  • Spectrum Pharmaceuticals
  • Partner Therapeutics
  • Pfizer
  • Myelo Therapeutics
  • Cellerant Therapeutics
  • Sandoz (Subsidary of Novartis AG)
  • BeyondSpring Pharmaceuticals
  • Enzychem Lifesciences Corporation
  • Tianjin SinoBiotech
  • S&D Pharma SK s.r.o.
  • Generon (Shanghai) Corporation Ltd.
  • PhytoHealth Corporation
  • Dong-A ST Co.
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll